'Pinas, gagawing testingan ng gamot ng South Korea kontra-COVID

ni Mary Gutierrez Almirañez | April 12, 2021

Gaganapin sa ‘Pinas ang clinical trial ng bakunang EuCorVac-19 na gawa ng South Korea upang labanan ang lumalaganap na COVID-19 pandemic, ayon sa Glovax Biotech Corporation ngayong araw, Abril 12.

Ayon kay CEO Giovanni Alingog, “The reason we wanted to do a clinical trial in the Philippines is most of the companies that were given EUA (emergency use authorization) in our country have not done a clinical trial locally. The reason we wanted to trial locally is to show, for ethnicity purposes, for Filipinos, that the vaccine is also effective and safe.”

Ngayong Abril ay nakatakdang isagawa ang combined phase 1 at phase 2 trial ng EuCorVac-19.

Batay pa sa pag-aaral, nagtataglay ito ng 91% hanggang 95% na efficacy rate.

Dagdag ni Alingog, “Because of the emergency purposes or the need of vaccine, we are asking the clinical research organizations and our FDA (Food and Drug Administration) to fast-track a bit our clinical trial so we can serve the Filipino people with a quality and safe vaccine from Korea.”

Samantala, iginiit naman ni Department of Health (DOH) Secretary Francisco Duque III na nakikipagtulungan na rin ang Glovax sa Department of Science and Technology (DOST) upang makapag-develop ang ‘Pinas ng sariling bakuna kontra COVID-19.

Sa ngayon, ang may emergency use authorization (EUA) pa lang na bakuna ay ang Pfizer-BioNTech, AstraZeneca, CoronaVac ng Sinovac, at ang Sputnik V ng Gamaleya Institute.

Pfizer-BioNTech COVID-19 vaccine, aprub na sa ‘Pinas

ni Ronalyn Seminiano Reonico | January 14, 2021

Binigyan na ng emergency use authorization (EUA) ng Food and Drug Administration (FDA) ang Pfizer-BioNTech COVID-19 vaccine kung kaya maaari na itong magamit sa bansa, ayon kay FDA Director General Eric Domingo.

Pahayag ni Domingo, "After thorough review, the FDA is granting EUA to Pfizer-BioNTech COVID-19. The interim data from the ongoing Phase 3 trial shows the vaccine has an efficacy rate of 95% in the study population and at least 92% among all racial groups. The EUA means the benefits outweigh the known and potential risks.

"This is effective immediately.”

Samantala, nilinaw ni Domingo na ang pagbibigay ng EUA ay hindi rin umano nangangahulugan na maaaring ibenta commercially ang naturang bakuna.

Unang Pinoy nurse na naturukan ng COVID vaccine, nakaramdam ng side effects

ni Ronalyn Seminiano Reonico | December 14, 2020

Nakaranas ng ilang “very common” side effects ng pagpapabakuna ang isang Filipino nurse sa United Kingdom na naturukan ng Pfizer-BioNTech COVID-19 vaccine noong Miyerkules.

Kinilala ang naturang nurse na si Leo Quijano at aniya ay marami na ring Pinoy nurses ang naturukan ng naturang bakuna.

Aniya, “So far, this is my pang-apat na araw ko na po after nag-vaccination ako ng COVID-19 vaccine. Wala naman akong nararamdaman so far.”

Saad pa ni Quijano, “A day after ng injection, nagkaroon ako ng mild body pain, tiredness, at saka mild fever. Pero, nawala rin po the next day because I took some paracetamol.”

Hinikayat din ni Quijano ang mga kapwa-Pinoy na magpabakuna kontra COVID.

Aniya, “The reason why I'm doing this interview is to spread awareness para ma-share rin po 'yung mga experiences ko para mawala po 'yung anxiety at saka agam-agam noong mga kababayan natin.

“Nakakatakot kasi marami nang nangyari before na mga reaction to a certain vaccination diyan sa atin. Pero, I bet this one so far is safe kasi pinag-aralan naman po before it becomes available to the public.”

Sa December 31 naman ang susunod na dose ng vaccine kay Quijano.